Daily Anesthesiology Research Analysis
Three impactful studies shape perioperative anesthesia practice this cycle: (1) the fifth edition ASRA guidelines update regional anesthesia management in patients on antithrombotic/thrombolytic therapy with pragmatic, safety-focused recommendations; (2) a Bayesian network meta-analysis compares pediatric cardiothoracic regional analgesia techniques, highlighting opioid-sparing benefits; and (3) a multicenter observational study links intraoperative ulinastatin to lower postoperative delirium af
Summary
Three impactful studies shape perioperative anesthesia practice this cycle: (1) the fifth edition ASRA guidelines update regional anesthesia management in patients on antithrombotic/thrombolytic therapy with pragmatic, safety-focused recommendations; (2) a Bayesian network meta-analysis compares pediatric cardiothoracic regional analgesia techniques, highlighting opioid-sparing benefits; and (3) a multicenter observational study links intraoperative ulinastatin to lower postoperative delirium after cardiac surgery, with mechanistic support via endothelial glycocalyx preservation.
Research Themes
- Regional anesthesia safety with antithrombotic therapy
- Opioid-sparing pediatric cardiothoracic analgesia
- Delirium prevention via endothelial glycocalyx protection in cardiac surgery
Selected Articles
1. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition).
This fifth edition provides safety-focused, evidence-based recommendations for regional and neuraxial anesthesia in patients receiving antithrombotic or thrombolytic therapy. Notable updates include adopting ‘low-dose’/‘high-dose’ terminology, conservative interruption intervals, and guidance on when drug-specific assays can inform timing of blocks and catheter management.
Impact: These guidelines directly influence perioperative decision-making globally and reduce the risk of neuraxial hematoma in anticoagulated patients. The reframed dosing and lab testing approach offers practical clarity for complex antithrombotic regimens.
Clinical Implications: Clinicians can align block timing and catheter management with conservative interruption intervals, stratified by low/high dose categories and complemented by drug-specific assays when available. This supports safer regional/neuraxial techniques in patients on DOACs, heparins, antiplatelets, and fibrinolytics.
Key Findings
- Terminology shift to ‘low dose’ and ‘high dose’ replaces ‘prophylactic/therapeutic’ to better reflect clinical dosing contexts.
- Conservative, safety-first interruption intervals are maintained to minimize neuraxial bleeding risk in rare but catastrophic events.
- Drug-specific assays (e.g., anti-Xa, direct oral anticoagulant levels) are suggested in select scenarios to guide timing of neuraxial procedures.
- Guideline is reorganized and condensed while clearly indicating changes from prior editions.
Methodological Strengths
- Evidence-based synthesis spanning multiple antithrombotic classes with explicit recommendations.
- Clear operational guidance on laboratory assays and timing, enhancing applicability.
Limitations
- True incidence of neuraxial hemorrhage is extremely low, limiting high-quality randomized evidence.
- Conservative intervals may delay care in certain scenarios and require local adaptation to resources and assays.
Future Directions: Prospective registries and pharmacodynamic studies to validate lab thresholds and refine safe intervals for newer agents; evaluation of outcomes with assay-guided neuraxial strategies.
Hemorrhagic complications associated with regional anesthesia are extremely rare. The fifth edition of the American Society of Regional Anesthesia and Pain Medicine's Evidence-Based Guidelines on regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy reviews the published evidence since 2018 and provides guidance to help avoid this potentially catastrophic complication.The fifth edition of the American Society of Regional Anesthesia and Pain Medicine's Evidence-Based Guidelines on r
2. Regional Analgesia in Pediatric Cardiothoracic Surgery: A Bayesian Network Meta-Analysis.
Across 24 RCTs (n=1602), all 13 regional techniques reduced 24-hour opioid consumption after pediatric cardiothoracic surgery. Thoracic retrolaminar block had the largest opioid-sparing effect; time to first rescue was longest with pectoral nerve blocks, and PONV incidence was lowest with epidural and transversus thoracis muscle plane blocks. Heterogeneity limits indirect comparisons.
Impact: This analysis provides comparative efficacy data to guide block selection in a high-stakes pediatric population where opioid minimization and recovery optimization are critical.
Clinical Implications: Consider thoracic retrolaminar block for maximal opioid-sparing and pectoral nerve blocks for prolonged analgesia; epidural and transversus thoracis muscle plane blocks may lower PONV. Individualize technique based on surgical approach, expertise, and risk profile, and standardize outcome tracking.
Key Findings
- Network meta-analysis of 24 RCTs (n=1602) across 13 regional techniques showed universal reduction in 24-hour opioid use.
- Thoracic retrolaminar block ranked best for opioid consumption reduction; pain score advantages were modest except immediately postoperative.
- Time to first rescue analgesic was longest with pectoral nerve blocks; PONV incidence was lowest with epidural and transversus thoracis muscle plane blocks.
- Indirect comparisons were limited by heterogeneity across studies.
Methodological Strengths
- Bayesian network meta-analysis enabling comparative ranking across multiple techniques.
- Restriction to randomized trials enhances internal validity.
Limitations
- Heterogeneity in block techniques, dosing, and outcome measures limits precision of indirect comparisons.
- Sparse head-to-head trials between certain blocks; safety outcomes variably reported.
Future Directions: Conduct adequately powered head-to-head RCTs with standardized dosing, sedation, and safety outcomes; evaluate long-term recovery metrics and enhanced recovery pathways.
Various regional analgesia techniques are used to reduce postoperative pain in pediatric patients undergoing cardiothoracic surgeries. This study aimed to determine the relative efficacy of regional analgesic interventions. PubMed, EMBASE, Web of Science, and Cochrane databases were searched to identify all randomized controlled studies evaluating the effects of regional block after cardiothoracic surgery. The primary endpoint was opioid consumption within 24 hours postoperatively, Pain scores, the time
3. Ulinastatin treatment mitigates glycocalyx degradation and associated with lower postoperative delirium risk in patients undergoing cardiac surgery: a multicentre observational study.
Across a large retrospective cohort (n=6522) with propensity matching and a validating prospective cohort (n=241), intraoperative ulinastatin use was associated with reduced postoperative delirium after cardiac surgery (prospective adjusted OR 0.392). In vitro, ulinastatin mitigated endothelial glycocalyx degradation, providing a biologic mechanism.
Impact: Links a feasible intraoperative intervention to lower delirium risk and identifies endothelial glycocalyx preservation as a mechanistic target in cardiac surgery.
Clinical Implications: Ulinastatin may be considered within multimodal delirium prevention strategies in cardiac surgery, pending randomized trials. Monitoring and targeting endothelial glycocalyx integrity could inform perioperative anti-inflammatory protocols.
Key Findings
- Intraoperative ulinastatin administration was associated with significantly lower postoperative delirium in a 6,522-patient retrospective cohort (supported by propensity score matching).
- A 241-patient prospective cohort validated the association (adjusted OR 0.392, 95% CI 0.157–0.977).
- In vitro assays showed ulinastatin mitigates endothelial glycocalyx degradation after ischemia-reperfusion stress, suggesting a mechanistic basis.
Methodological Strengths
- Large multicenter retrospective cohort with multivariable analysis and propensity score matching.
- Prospective cohort validation plus mechanistic in vitro experiments.
Limitations
- Observational design cannot exclude residual confounding; dosing and timing heterogeneity likely.
- Delirium ascertainment methods and generalizability outside study settings may vary.
Future Directions: Randomized controlled trials to confirm causality and define optimal dosing/timing; biomarker-driven strategies (e.g., syndecan-1) to monitor glycocalyx and personalize therapy; assess long-term cognitive outcomes.
BACKGROUND: Ulinastatin (UTI), recognized for its anti-inflammatory properties, holds promise for patients undergoing cardiac surgery. This study aimed to investigate the relationship between intraoperative UTI administration and the incidence of delirium following cardiac surgery. METHODS: A retrospective analysis was performed on a retrospective cohort of 6,522 adult cardiac surgery patients to evaluate the relationship between UTI treatment and the incident of postoperative delirium (POD) in patients ongoing cardiac surgery. This was followed by a prospective observational cohort study of 241 patients and an in vitro study to explore the findings and the potential role of UTI in preventing cardiac ischemia-reperfusion induced glycocalyx degradation. RESULTS: Both univariate and multivariate logistic regression analyses in retrospective cohort indicated that intraoperative administration of UTI was associated with a significant lower risk of POD among cardiac surgery patients, a finding confirmed through employing propensity score matching. The subsequent prospective observational cohort further supported these findings (adjusted Odds Ratio = 0.392, 95% CI: 0.157-0.977, P = 0.044). Furthermore, UTI mitigated glycocalyx degradation, as demonstrated by in vitro study. CONCLUSIONS: UTI administration may mitigate glycocalyx degradation, potentially lowering the risk of POD in cardiac surgery patients, offering valuable insights for future interventions to prevent POD and enhance patient outcomes. Trial registration number ClinicalTrials.gov (No. NCT06268249). Retrospectively registered 4 February 2024.